The CDK inhibitors in cancer research and therapy

Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias

(2011) J. E. Karp et al.   BLOOD

A Phase I Study of Flavopiridol in Combination With Gemcitabine and Irinotecan in Patients With Metastatic Cancer

(2010) Houman M. Fekrazad et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies

(2010) Christophe Le Tourneau et al.   EUROPEAN JOURNAL OF CANCER

Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias

(2010) W. Blum et al.   HAEMATOLOGICA

Cyclin D3/CDK11p58 Complex Involved in Schwann Cells Proliferation Repression Caused by Lipopolysaccharide

(2010) Yinong Duan et al.   INFLAMMATION

Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

(2010) Wei-Gang Tong et al.   JOURNAL OF CLINICAL ONCOLOGY

Alteration in the expression of cdk4 and cdk6 proteins in oral cancer and premalignant lesions

(2010) Sopee Poomsawat et al.   JOURNAL OF ORAL PATHOLOGY & MEDICINE

Combined genetic effect of CDK7 and ESR1 polymorphisms on breast cancer

(2009) Sujee Jeon et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors

(2009) D. Rathkopf et al.   CLINICAL CANCER RESEARCH

Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease

(2009) Thomas S. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Single-nucleotide polymorphisms in the promoter of the CDK5 gene and lung cancer risk in a Korean population

(2009) Hyo Seon Choi et al.   JOURNAL OF HUMAN GENETICS

Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients

(2009) W. Berkofsky-Fessler et al.   MOLECULAR CANCER THERAPEUTICS

A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer

(2009) Richard D. Carvajal et al.   PANCREATOLOGY

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

(2008) M. A. Phelps et al.   BLOOD

An Unusual Member of the Cdk Family: Cdk5

(2008) Fatema A. Dhariwala et al.   CELLULAR AND MOLECULAR NEUROBIOLOGY

Phase I Study of Flavopiridol in Combination with Paclitaxel and Carboplatin in Patients with Non–Small-Cell Lung Cancer

(2008) Saby George et al.   Clinical Lung Cancer

Characterization of Cyclin L1 and L2 Interactions with CDK11 and Splicing Factors

(2008) Pascal Loyer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY